The Long and Short

Huntsman looks like a rising star

Meredith Contente | July 9, 2021

This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors. This material does not constitute research.

The Huntsman Corporation keeps doing the rights things to earn an investment grade rating from the three largest agencies. It has recently refinanced debt and pushed out maturities to complement steady reduction in total debt. With earnings also likely to improve, leverage should keep going down. Huntsman could grab investment grades across the agencies within 12 months, and there is clear upside in its debt.

HUN (Baa3/BB+/BBB-) recently tapped the market with proceeds used to redeem the company’s $400 million notes maturing 11/15/22. The redemption pushed out the company’s nearest debt maturity until 2025 while reducing overall interest costs. Management has demonstrated its commitment to investment grade ratings as it has reduced debt by nearly $800 million since fiscal year-end 2019 with divestiture proceeds, while focusing on restructuring efforts to improve its overall margin profile. While total company leverage is in the realm of investment ratings, 2.6x on a gross basis and 1.7x on a net basis, it is expected to improve as EBITDA is forecasted to grow strongly in 2H21. That said, gross leverage is expected to decline below 2.0x. Additionally, FFO/debt, a key metric used by S&P when determining ratings, should increase above S&P’s 40% requirement. HUN could get rated IG by all three ratings agencies within 12 months. There is further upside in HUN spreads and particularly in HUN 2.95% 2031 bonds given the low dollar price and spread pick-up relative to DOW Chemical (DOW – Baa2/BBB/BBB+). Currently, the spread difference between the two credits in the 10-year part of the curve is close to 50 bp (g-spread). Note that in 5-year CDS, HUN trades nearly 8 bp through DOW.

Exhibit 1. BBB Chemical 7-year-10-year Curve

Source: Bloomberg TRACE; APS

Balance sheet and liquidity are strong

As mentioned above, HUN is currently levered 2.6x on a gross basis and 1.7x on a net basis, which are strong enough credit metrics to garner investment grade ratings at all three rating agencies. When you exclude affiliate debt, HUN’s metrics are even stronger, at 2.0x gross leverage and 1.2x net leverage. HUN’s most recent $400 million debt issuance did not increase leverage as proceeds were used to make-whole its $400 million issue which was set to mature in November 2022. Additionally, liquidity at the end of the quarter stood at $1.9 billion reflecting cash on hand of $673 million and an untapped revolver of $1.2 billion. Liquidity further benefits from solid free cash flow generation. HUN should generate just over $300 million of free cash flow this year, which will more than cover the company’s dividend payments which are expected to total approximately $165 million for the year. HUN has a solid track record of strong and consistent free cash flow conversion which has averaged 42.5% over the past four years and is forecasted to now be 40% for 2021, five percentage points higher than management’s previous expectations.

Exhibit 2. HUN Adjusted Free Cash Flow Conversion (2017-2021F)

(1) Excludes taxes paid on sale of businesses
Source: HUN 1Q21 Earnings Presentation

End-Market Recovery Supports Full-Year Growth

HUN’s first quarter results highlighted sequential volume growth across every business line except for Polyurethanes. However, management noted on the earnings call that quarterly volume decline largely reflected a planned inventory build. Additionally, management noted that they are witnessing positive growth trends in construction and elastomer markets that should continue throughout the year. In Performance Products, volume increased 5% sequentially and management expects to witness volume growth for the year across all of Performance Products’ core markets. Furthermore, pricing growth has been strong and price increases are expected to offset raw material inflation. In Advanced Materials, HUN witnessed volume growth across all core markets except Aerospace. However, management expect trends to continue to improve for the remainder of the year for the Advanced Materials unit, including Aerospace. Lastly Textile Effects saw volumes improve on both a yoy and sequential basis due to improved global demand. HUN has forecasted that Textile Effects will continue to see recovery in core markets, as well as favorable trends in sustainable solutions.

Synergies and cost realignment on track

HUN continues to target $120 million of annualized run rate synergies from recent acquisitions by mid-2023. Management noted that they have now exceeded the $20 million target they set by combining the polyurethane spray foam businesses and creating the Huntsman Building Solutions Platform. With respect to the CVC Thermostat acquisition, which closed 5/18/20, HUN has already achieved an annualized synergy run rate of $9 million and is on target to achieve $15 million by year-end. They also remain expect to hit their $8 million synergy target related to the Gabriel Performance Products acquisition, (completed 1/15/21) by early 2023. This would put HUN on track to achieve its run-rate target of $90 million by year end, with that target to grow by an additional $30 million over the next two years.

On the cost realignment side, HUN continues to make solid progress against its goals. The Polyurethane business has been undergoing the largest makeover and is expected to produce nearly $40 million in run-rate savings by mid-2022. To date, management noted that they have achieved $15 million of those savings. With respect to Advanced Materials, $7 million of management’s $10 million target has already been achieved.

Exhibit 3. HUN Cost Realignment & Synergy Update

Source: HUN 1Q21 Earnings Presentation

EBITDA returning to normalized levels

While management noted that they are “a far cry from all cylinders running”, they did note that all businesses within their portfolio are approaching or have already achieved historical normalized EBITDA levels. The only exceptions to this are the Chinese and European MDI component polymeric cells, which have been seeing higher than normal EBITDA margins, and Aerospace which continues to underperform and is running approximately $50 million shy of normalized levels. HUN expects Aerospace to fully recover over the next few years. That said, management is optimistic that it can produce $1.1 billion of adjusted EBITDA this year, a level not seen since 2018. This would translate to an adjusted EBITDA margin 15.1%, up nearly 600 bp from year end 2020, and up nearly 80 bp from 2018.

Meredith Contente
meredith.contente@santander.us
1 (646) 776-7753

This material is intended only for institutional investors and does not carry all of the independence and disclosure standards of retail debt research reports. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.

This message, including any attachments or links contained herein, is subject to important disclaimers, conditions, and disclosures regarding Electronic Communications, which you can find at https://portfolio-strategy.apsec.com/sancap-disclaimers-and-disclosures.

Important Disclaimers

Copyright © 2024 Santander US Capital Markets LLC and its affiliates (“SCM”). All rights reserved. SCM is a member of FINRA and SIPC. This material is intended for limited distribution to institutions only and is not publicly available. Any unauthorized use or disclosure is prohibited.

In making this material available, SCM (i) is not providing any advice to the recipient, including, without limitation, any advice as to investment, legal, accounting, tax and financial matters, (ii) is not acting as an advisor or fiduciary in respect of the recipient, (iii) is not making any predictions or projections and (iv) intends that any recipient to which SCM has provided this material is an “institutional investor” (as defined under applicable law and regulation, including FINRA Rule 4512 and that this material will not be disseminated, in whole or part, to any third party by the recipient.

The author of this material is an economist, desk strategist or trader. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM or any of its affiliates may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.

This material (i) has been prepared for information purposes only and does not constitute a solicitation or an offer to buy or sell any securities, related investments or other financial instruments, (ii) is neither research, a “research report” as commonly understood under the securities laws and regulations promulgated thereunder nor the product of a research department, (iii) or parts thereof may have been obtained from various sources, the reliability of which has not been verified and cannot be guaranteed by SCM, (iv) should not be reproduced or disclosed to any other person, without SCM’s prior consent and (v) is not intended for distribution in any jurisdiction in which its distribution would be prohibited.

In connection with this material, SCM (i) makes no representation or warranties as to the appropriateness or reliance for use in any transaction or as to the permissibility or legality of any financial instrument in any jurisdiction, (ii) believes the information in this material to be reliable, has not independently verified such information and makes no representation, express or implied, with regard to the accuracy or completeness of such information, (iii) accepts no responsibility or liability as to any reliance placed, or investment decision made, on the basis of such information by the recipient and (iv) does not undertake, and disclaims any duty to undertake, to update or to revise the information contained in this material.

Unless otherwise stated, the views, opinions, forecasts, valuations, or estimates contained in this material are those solely of the author, as of the date of publication of this material, and are subject to change without notice. The recipient of this material should make an independent evaluation of this information and make such other investigations as the recipient considers necessary (including obtaining independent financial advice), before transacting in any financial market or instrument discussed in or related to this material.